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Abstract: Hepatitis C virus (HCV) is one of the major viruses affecting the world today. 
It is a highly variable virus, having a rapid reproduction and evolution rate. The variability 
of genomes is due to hasty replication catalyzed by nonstructural protein 5B (NS5B) which 
is also a potential target site for the development of anti-HCV agents. Recently, the US Food 
and Drug Administration approved sofosbuvir as a novel oral NS5B inhibitor for the treatment 
of HCV. Unfortunately, it is much highlighted for its pricing issues. Hence, there is an urgent 
need to scrutinize alternate therapies against HCV that are available at affordable price and do 
not have associated side effects. Such a need is crucial especially in underdeveloped countries. 
The search for various new bioactive compounds from plants is a key part of pharmaceuti-
cal research. In the current study, we applied a pharmacoinformatics-based approach for the 
identification of active plant-derived compounds against NS5B. The results were compared 
to docking results of sofosbuvir. The lead compounds with high-binding ligands were further 
analyzed for pharmacokinetic and pharmacodynamic parameters based on in silico absorption, 
distribution, metabolism, excretion, and toxicity (ADMET) profile. The results showed the 
potential alternative lead compounds that can be developed into commercial drugs having high 
binding energy and promising ADMET properties.
Keywords: hepatitis C, NS5B inhibitors, molecular docking, AutoDock Vina, ADMET, 
sofosbuvir, phytochemicals
Introduction
Hepatitis C virus (HCV) is a major cause of liver-related infectious diseases, including 
hepatitis C, liver cirrhosis, fibrosis, and hepatocellular carcinoma. Approximately 
170 million people worldwide are affected by hepatitis C. About three to four million 
new infections are developing every year and turn into chronic infections.1 HCV is a 
single-stranded positive-sense RNA virus of family Flaviviridae. The HCV genome 
(~9.6 kb), with a single open-reading frame, encodes a single and long protein of about 
3,010 amino acids which is further processed to make several active proteins by HCV 
serine proteases (NS3, NS4A). These active proteins include three structural (core, E1, 
and E2) and seven nonstructural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and 
NS5B). The HCV genome has conserved 5′ and 3′ untranslated regions (UTRs) where 
5′ UTR possesses an internal ribosome entry site that recruits host ribosome to translate 
its genome and 3′ UTR is involved in viral replication and its packaging.2 Among all 
HCV proteins, NS3, NS5A, and NS5B are potential drug targets for the development 
of anti-HCV agents.3
Phylogenetically, HCV is classified into seven major groups and further 
subclassified into 67 subtypes.4 Among these variants, genotype 3 is rather dominant 
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in Southeast Asia and less prevalent in certain European 
countries. In addition, fast fibrosis progression has been 
observed in genotype 3.5 Apart from genotype variation, 
HCV exists as a heterogeneous population of different viruses 
called quasispecies, within each infected individual.6,7 The 
variability of genomes is mainly due to rapid replication 
catalyzed by NS5B. NS5B is an error-prone RNA-dependent 
RNA polymerase (RdRp) with inefficient proofreading abil-
ity. NS5B belongs to a class of tail-anchored proteins with a 
confirmation resembling that of fingers, palm, and thumb of 
the right hand.8,9 The palm domain contains the active site 
of polymerase enzyme, and the finger and thumb modulate 
interactions with RNA template. The finger and thumb are 
considered to have multiple interactions with each other 
which encircle the active site and form a tunnel that guides 
RNA template directly to the active site. RNA synthesis is 
regulated by a flexible beta hairpin loop present in the palm 
domain.10,11 NS5B replicates RNA in a semiconservative 
manner and initiates de novo synthesis. Various NS5B inhibi-
tors have been developed that mimic natural polymerase 
substrates and can inhibit their catalytic efficiency.12 These 
inhibitors can be classified as either nucleoside inhibitors 
or non-nucleoside inhibitors. Nucleoside inhibitors such 
as ribavirin cause premature termination of RNA synthesis 
and include purine, pyrimidine, or miscellaneous nucleoside 
inhibitor classes. The non-nucleoside inhibitors include 
allosteric, active site and miscellaneous non-nucleoside 
inhibitors.13 However, available drugs are associated with 
adverse side effects that pose a need for the development of 
an effective drug.
Recently, sofosbuvir has been approved by the US Food 
and Drug Administration as a novel oral antiviral drug to 
target NS5B for the treatment of HCV.14,15 Sofosbuvir, 
being a uridine nucleotide analog, targets the catalytic 
site of NS5B polymerase, thus serving as a non-obligate 
chain terminator.16 Common side effects associated with 
sofosbuvir treatment include fatigue, headache, nausea, 
rash, and irritability. Moreover, the drug is considered 
less effective in genotype 3, especially in the presence of 
cirrhosis.17 Despite its potential for HCV treatment, sofos-
buvir is much highlighted for its pricing controversies. 
In fact, the drug is given in combination with other HCV 
drugs, and a 24-week-long treatment plan costs as much 
as $168,000 when used against genotype 3. This high cost 
makes it unaffordable in underdeveloped countries where 
genotype 3 is prevalent. Hence, there is a vital need to 
scrutinize alternate therapies against HCV with minimal 
side effects and low cost.
The search for various new bioactive compounds from 
plants is a key part of pharmaceutical research.18,19 Plants have 
been used to treat several human diseases for centuries. Not 
surprisingly, many modern drugs have also been developed 
from molecules that are isolated from natural sources.20 Plants 
are rich in phytochemicals such as phenolics, alkaloids, and 
flavonoids. These compounds, being natural, are associated 
with least side effects and cost. Hence, this mode of drug 
production may lead to the development of less expensive 
treatments. One approach of screening bioactive compounds 
is through molecular docking.21 Comparative studies of 
phytochemicals provides the best avenue for searching new 
economic plant for HCV,22,23 and some natural active com-
pounds have been revealed to have antiviral activities against 
hepatitis B virus and HCV.24–26
In addition to high potency and good docking results, 
a drug should have an impressive absorption, distribution, 
metabolism, excretion, and toxicity (ADMET) profile. 
Thousands of potential compounds fail to reach drug status 
because of poor pharmacodynamic (PD) and pharmacoki-
netic (PK) properties each year.27 These characteristics 
depend upon the physiochemical properties of the compound 
that determine its ADMET. A drug’s absorption usually 
depends upon its lipophilicity and solubility.28 The more a 
drug is lipophilic, the greater is its rate of absorption in the 
bloodstream due to greater affinity of lipophilic compounds 
for metabolic enzymes. Once absorbed, the drug is distributed 
across the body. This is majorly determined by the affinity 
of the drug for blood and tissues. Lipophilicity also affects 
the binding of a drug with the protein.29 The more the drug is 
lipophilic, the greater is its distribution. A drug is metabolized 
and converted into a more water-soluble compound so that 
it can be easily eliminated from the body. The metabolism 
is generally carried out by cytochrome P450 (CYP450) 
enzymes.30 Interestingly, more than 60 isoforms of CYP450 
are present in the body with hundreds of genetic variations 
possible.31 The variety accounts for their susceptibility toward 
various toxins. The kidney and liver are mainly involved in 
the excretion of drugs.32 The ADMET profiling is usually 
done in the end stages of drug development accounting for 
a high risk, greater expense, and time. Alternatively, in silico 
approach is applied to provide a more efficient route to drug 
development. The PK properties are now determined as a 
mathematical description of the rates of absorption, distribu-
tion, metabolism, and excretion (ADME) processes and of 
concentration–time relationships.32
Considering these critical requirements, the current 
in silico study was undertaken to find efficient NS5B 
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polymerase inhibitors through comparative study of vari-
ous phytochemicals found in the literature which possess 
anti-HCV properties. The potential compounds were also 
evaluated for their PK and PD properties. The efficacy of 
all compounds was compared with that of sofosbuvir with 
the sole purpose of providing a cheaper alternative HCV 
therapy.
Materials and methods
Proteins and ligands
Several crystal structures of viral protein NS5B have been 
solved with their potential inhibitors and are present in struc-
tural databases. The crystallographic structures of NS5B in 
complex with its inhibitors were taken from Brookhaven 
Protein Data Bank (PDB). The crystal structures of NS5B 
are present in the Protein Data Bank with 2WCX,33 2BRL, 
2BRK,34 2XWY,35 and 2DXS36 codes. The residues making 
binding pockets for the inhibitor were investigated. The bind-
ing site of NS5B was further validated by using COACH,37 
Castp,38 and 3DLigandSite servers.39 An extensive literature 
review was done to know about the ligands that act as inhibi-
tors. Compounds found in various plants, reported in the lit-
erature to possess activity against HCV, were selected. These 
compounds belong to different classes of phytochemicals such 
as flavonoids, lignans, alkaloids, and coumarins (Table S1). 
A total of 84 ligands were short listed, and their structures 
were downloaded in SDF format from different small-
compound databases including PubChem,40 Chemspider,41 
Zinc,42 and DrugBank.43 The SDF format was converted to 3D 
Mol format using ChemOffice 2012 (Cambridge Soft Corp., 
Cambridge, MA, USA, http://www.cambridgesoft.com).
in silico analysis of drug likeness 
and aDMeT properties
Selected compounds were subjected to further selection on 
the basis of Lipinski’s rule of five (Ro5),44 and compounds 
without any Ro5 violations were eliminated. This was simply 
done by using Mcule,45 Cresset, and Molinspiration server 
(http://www.molinspiration.com/cgi-bin/properties) for cal-
culation of their physicochemical properties. The drug like-
ness of screened compounds was further confirmed by using 
Marvinsketch (http://www.chemaxon.com/marvin/sketch/
index.jsp). The ADMET properties of the filtered compounds 
were found to know about the rate and extent of ADMET 
threats of compounds through blood, body fluids, tissues, and 
excretory material of the body. A wide range of tools was 
used for ADMET assessment. These include OSIRIS prop-
erty explorer (http://www.organic-chemistry.org/prog/peo/), 
Discovery Studio 4.0 (Accelrys Software Inc.), Cresset, 
admetSAR (http://1mmd.ecust.edu.cn:8000/),27 ADMET 
prediction suite by ACD/Labs, and Molsoft (http://molsoft.
com/mprop/). Ligands were selected by calculating ligands 
drug likeness based upon Lipinski’s Ro5. Selected ligands 
were docked in to the binding pocket of NS5B protein.
Pre-docking procedure
In order to prepare the selected compounds for docking, 
hydrogens and Gasteiger charges were added. Charges 
were merged, and nonpolar hydrogens, lone pairs, water 
molecules, and nonstandard residues were removed. Energy 
minimization and geometry optimization of all structures, 
ligands, and proteins were performed using general purpose 
semiempirical molecular orbital package (MOPAC) version 
2012 with improved accuracy of semiempirical method PM7. 
A grid with a dimension of 30 Å ×30 Å ×30 Å was centered 
covering the binding pocket of NS5B protein. AutoDockVina 
(Scripps Research Institute, La Jolla, CA, USA) was 
employed in order to perform molecular docking.46 Standard 
autodock protocol was used with ligands. AutoDockVina 
was set up on a DELL Inspiron Core i7 workstation under 
operating system as Ubuntu 12. Protein complexes of all 
filtered ligands were further analyzed using UCSF Chimera 
1.9 (Resource for Biocomputing, Visualization and Informat-
ics, University of California, San Francisco, CA, USA),47 
Discovery Studio 4.0 (Accelrys Software Inc.),48 and Pymol 
(The PyMOL Molecular Graphics System, Version 1.5.0.4, 
Schrödinger, LLC).49
Results and discussion
The aim of the current study was to elucidate alternative 
inhibitory compounds against NS5B protein and to find the 
binding pocket against viral RdRp. A total number of 84 
plant-derived compounds were chosen from the literature. In 
silico virtual screening of selected compounds was performed 
on the basis of Lipinski’s Ro5 and physicochemical proper-
ties, to assess the drug likeness (Table 1). The compounds 
showing strong binding affinity for NS5B viral protein were 
selected for further investigations. Binding affinity calcula-
tions for all 30 filtered compounds were carried out using 
AutoDockVina. Out of 30 filtered compounds, ten showed 
strong binding affinity for the target. These results were 
compared to the docking result of the recently approved drug 
against NS5B, namely sofosbuvir. Further analysis includes 
PK and PD properties of screened compounds as early drug 
discovery process. The ADMET profile was analyzed to infer 
the suitable lead compound. The criteria for selection of best 
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
4.
58
.2
53
.5
7 
on
 3
0-
Se
p-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Drug Design, Development and Therapy 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1828
Mirza et al
T
ab
le
 1
 P
re
di
ct
ed
 d
ru
g-
lik
en
es
s 
pr
op
er
tie
s 
of
 p
ot
en
tia
l c
om
po
un
ds
Li
ga
nd
 n
am
e
M
W
Lo
g 
P
Lo
g 
S
H
B
A
H
B
D
N
um
be
r 
 
of
 r
ot
b
P
SA
N
um
be
r 
of
  
vi
ol
at
io
ns
R
ef
ra
ct
iv
it
y
N
um
be
r 
 
of
 a
to
m
s
H
ea
vy
  
at
om
s
D
ru
g-
lik
en
es
s 
 
sc
or
e
D
ru
g 
 
sc
or
e
1
n
ar
in
ge
ni
n
27
2.
25
2
2.
50
99
-2
.6
4
5
3
1
86
.9
9
0
71
.5
70
5
32
20
1.
9
0.
84
2
T
ry
ph
an
th
ri
ne
24
8.
23
5
1.
93
01
-3
.7
5
4
0
0
51
.9
6
0
70
.7
72
5
27
19
3.
28
0.
84
3
D
ic
ou
m
ar
in
33
6.
29
3
2.
90
14
-6
.8
3
6
2
2
10
0.
88
0
92
.0
25
37
25
1.
3
0.
43
4
sw
er
tia
ni
n
27
4.
22
5
2.
07
16
-4
.0
6
6
3
1
10
0.
13
0
72
.5
51
30
20
-0
.4
7
0.
34
5
D
io
sm
et
in
30
0.
26
2
2.
58
54
-2
.8
7
6
3
2
10
0.
13
0
80
.4
81
34
22
2.
07
0.
83
6
a
pi
ge
ni
n
27
0.
23
6
2.
57
68
-2
.8
6
5
3
1
90
.9
0
73
.9
89
30
20
1.
21
0.
47
7
h
on
ok
io
l
26
6.
33
3
4.
22
18
-4
.5
3
2
2
5
40
.4
6
0
84
.1
36
38
20
-3
.0
1
0.
12
8
lu
te
ol
in
28
6.
23
5
2.
28
24
-2
.5
6
6
4
1
11
1.
13
0
76
.0
12
31
21
1.
9
0.
84
9
T
ha
lip
or
ph
in
e
34
1.
4
3.
10
8
-3
.4
4
5
1
3
51
.1
6
0
10
0.
47
2
48
25
5.
81
0.
8
10
O
xy
m
at
ri
ne
26
4.
36
3
1.
78
1
0.
07
4
0
0
49
.7
4
0
82
.9
52
43
13
-3
.0
9
0.
5
11
W
ed
el
ol
ac
to
ne
31
4.
24
5
2.
81
78
-4
.0
7
7
3
1
11
3.
27
0
82
.3
23
33
23
-1
.0
8
0.
3
12
D
es
m
et
hy
lw
ed
el
ol
ac
to
ne
30
0.
21
9
2.
51
48
-3
.7
5
7
4
0
12
4.
27
0
77
.8
54
30
22
-1
.2
3
0.
3
13
Be
rb
er
in
e
33
6.
36
3.
09
63
-2
.3
4
5
0
2
40
.8
0
94
.8
74
43
25
1.
92
0.
56
14
a
nd
ro
gr
ap
ho
lid
e
35
0.
44
8
1.
96
26
-2
.9
5
5
3
3
86
.9
9
0
95
.2
14
4
55
25
-4
.5
9
0.
43
15
la
da
ne
in
31
4.
28
8
2.
88
84
-3
.1
9
6
2
3
89
.1
3
0
84
.9
5
37
23
-1
.6
9
0.
49
16
c
ur
cu
m
in
36
8.
37
8
3.
36
99
-3
.6
2
6
2
8
93
.0
6
0
10
2.
80
3
47
27
-3
.9
5
0.
4
17
g
en
is
te
in
27
0.
23
6
2.
57
68
-2
.7
3
5
3
1
90
.9
0
73
.9
89
30
20
1.
16
0.
17
18
lo
ga
ni
n
39
0.
38
2
-2
.1
50
8
-1
.1
6
10
5
5
15
5.
14
0
87
.3
66
53
27
-3
.9
2
0.
45
19
ep
ic
at
ec
hi
n
29
0.
26
7
1.
54
61
-1
.7
6
6
5
1
11
0.
38
0
74
.3
33
8
35
21
1.
92
0.
87
20
h
yp
op
hy
lla
nt
hi
n
43
0.
48
9
3.
65
43
-4
.1
8
7
0
8
64
.6
1
0
11
5.
29
8
61
31
2.
2
0.
38
21
Q
ue
rc
et
in
30
2.
23
5
1.
98
8
-2
.4
9
7
5
1
13
1.
36
0
78
.0
35
32
22
1.
6
0.
3
22
si
ly
m
ar
in
/s
ili
bi
ni
n
48
2.
43
4
2.
36
27
-3
.4
1
10
5
4
15
5.
14
0
12
0.
55
57
35
1.
64
0.
64
23
Ph
yl
la
nt
hi
n
41
8.
52
2
4.
03
14
-3
.4
3
6
0
13
55
.3
8
0
11
7.
68
2
64
30
3.
06
0.
67
24
lu
ci
do
ne
25
6.
25
2
2.
19
4
-2
.6
5
4
1
4
63
.6
0
70
.1
76
8
31
19
-1
.4
6
0.
55
25
Ja
tr
or
rh
iz
in
e
33
8.
37
6
3.
08
18
-2
.5
5
1
3
51
.8
0
97
.3
26
45
25
1.
4
0.
62
26
c
ar
ui
lig
na
n 
c
29
4.
29
9
1.
57
29
-1
.9
1
6
0
4
63
.2
2
0
73
.0
61
39
21
3.
84
0.
92
27
V
er
be
na
lin
38
8.
36
6
-1
.9
42
6
-1
.2
1
10
4
5
15
1.
98
0
86
.4
04
2
51
27
-6
.0
5
0.
44
28
g
er
an
yl
 a
ce
to
ne
19
4.
31
3
4.
04
83
-2
.8
6
1
0
6
17
.0
7
0
63
.8
57
36
14
-4
.5
9
0.
22
29
n
ob
ile
tin
40
2.
39
3
3.
51
16
-3
.8
5
8
0
7
85
.5
9
0
10
6.
87
2
51
29
3
0.
26
30
T
et
ra
de
ca
no
ic
 a
ci
d
22
8.
37
4.
77
21
-3
.7
2
1
12
37
.3
0
71
.1
83
8
44
16
-2
5.
22
0.
12
N
ot
es
: l
og
 P
 d
en
ot
es
 li
po
ph
ili
ci
ty
, a
nd
 lo
g 
S 
de
no
te
s 
aq
ue
ou
s 
so
lu
bi
lit
y.
 V
io
la
tio
ns
 r
ep
re
se
nt
 L
ip
in
sk
i’s
 r
ul
e-
of
-fi
ve
 v
io
la
tio
ns
.
A
bb
re
vi
at
io
ns
: M
W
, m
ol
ec
ul
ar
 w
ei
gh
t; 
h
Ba
, h
yd
ro
ge
n 
bo
nd
 a
cc
ep
to
r;
 h
BD
, h
yd
ro
ge
n 
bo
nd
 d
on
or
; r
ot
b,
 r
ot
at
ab
le
 b
on
ds
; P
sa
, p
ol
ar
 s
ur
fa
ce
 a
re
a.
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
4.
58
.2
53
.5
7 
on
 3
0-
Se
p-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Drug Design, Development and Therapy 2015:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1829
investigation of hcV-ns5B inhibitors
compounds were high binding affinity compared to sofosbu-
vir and good pharmacological properties. In the present study, 
only the result of these ten compounds will be discussed. 
Further, we reported inhibitory effect of compounds that will 
be the potential lead compounds for alternative drug therapy 
of HCV patients providing cheap and effective therapy in 
comparison to expensive sofosbuvir treatment.
Binding site analysis
The protein-binding site prediction servers validated the 
binding site residues of target protein. A superimposition 
of all five complexes further confirmed the most conserved 
interacting amino acids of NS5B (Figure 1). It was found that 
nine amino acids were actually involved in interactions with 
HCV-NS5B inhibitors. These interacting residues include 
Val37, Leu492, His428, Ala395, Leu392, Val494, Ala396, 
Arg503, Ile424, and Pro495, constituting the active site for 
HCV-NS5B. Furthermore, a deep groove, encompassing 
the binding pocket, was observed, thus providing space 
for inhibitors to strongly bind with the active site of NS5B 
(Figure 2). It was assumed that binding of drug in this deep 
groove will inhibit virus from replication, and it seems to be 
a promising mode of action to be chosen for designing drug 
candidates against HCV.
Figure 1 schematic diagram showing the binding modes of co-crystalline ligands with respective ns5B.
Notes: Conserved interacting residues are displaying in red circles. This figure was generated from a program LigPlot.69
Abbreviations: ns5B, nonstructural protein 5B; PDB, Protein Data Bank.
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Molecular docking study
Molecular docking of two molecules, the ligand and target, 
predicts the best ways of their interactions.50 In the current 
study, NS5B was docked with various plant-derived com-
pounds to find the best candidate that inhibits viral replica-
tion. A total of 84 phytochemicals having inhibitory effects 
against NS5B were screened for their maximum probable 
activity.
The binding pocket was determined by various crystal-
line structures and binding site prediction servers. A total 
of 30 ligands with high binding affinities for NS5B were 
obtained. The docking scores were represented along with 
hydrogen bonds, direct contacts based on van der Waals 
(vdW) radii, and interacting residues profiled in Table 2. 
Binding energies were the representative of how precisely 
the drug (ligand) binds to the target molecule (protein), and 
thus were taken as baseline comparison for selection of lead 
compounds in drug designing. Ninety-three percent of the 
ligands showed a binding score stronger than 8 kcal/mol on 
docking with NS5B. None of the ligands showed binding 
score weaker than -7.4 kcal/mol. Ligands with high affinity 
scores were naringenin, tryphanthrine, dicoumarin, swertia-
nin, diosmetin, apigenin, honokiol, luteolin, thaliporphine, 
and oxymatrine. Binding energies of these compounds ranged 
from -9.7 kcal/mol to -9 kcal/mol, which were stronger as 
compared to sofosbuvir (-6.2 kcal/mol). These ligands were 
found to interact mostly with NS5B via Leu392, Ala395, 
Ala396, His428, and Leu492 residues forming hydrogen 
and VdW interactions. It is inferred that these interactions 
stabilize the protein–ligand complex and lead to inhibitory 
activity on NS5B active site. Among molecular interactions, 
compounds, namely, naringenin, tryphanthrine, swertianin, 
diosmetin, luteolin, and thaliporphine were observed to 
form three hydrogen bonds, each mainly with Ala396 and 
Arg503. They were also seen to form VdW interactions 
mainly with His428, Val494, Leu492, Leu392, Pro495, and 
Ala395 (Table 2). Interestingly, all filtered compounds bind 
within a narrow groove line with their nonpolar and posi-
tively charged residues, and these ligands commonly interact 
with Val37, Leu392, Ala395, Ala396, His428, Leu492, and 
Figure 2 An inside view of binding pocket of HCV-NS5B, with a small drug molecule (naringenin) firmly bound.
Note: interpolated charge (color intensity from blue to red) of binding pocket residues (in sticks) is represented.
Abbreviations: hcV, hepatitis c virus; ns5B, nonstructural protein 5B.
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Val494 located in this groove (Figure 3). Comprehensively, 
it can be deduced that Leu492, Leu392, Val494, and Pro495 
residues are involved in VdW interactions with NS5B, while 
Cys146, Ala395, Ala396, His428, and Arg503 are largely 
involved in forming hydrogen bonds.
From the tabulated results (Table 2), it is clearly evident 
that all the 30 filtered compounds were successfully docked 
with the viral NS5B protein, with a binding affinity ranging 
between -7.4 kcal/mol and -9.7 kcal/mol as compared to 
sofosbuvir.
Prediction of ADME profile
Earlier, scanning of ADME properties was carried out at 
the end stage of drug discovery or during preclinical trials. 
As a result, more and more drugs failed to reach final stage 
because of their poor PK and PD profiles. In silico, a rather 
Table 2 Molecular docking analysis showing estimated binding energy, interacting residues, and molecular interactions of potential 
compounds in the binding site of hcV-ns5B
Ligand name Binding  
energy  
(kcal/mol)
VdW interacting residues Number  
of H-bonds
H-bonds interacting 
residues
Number  
of direct  
contact  
(all polar,  
nonpolar  
interactions)
naringenin -9.7 his428a, Val494, leu392,  
leu492, ala395
3 Thr399, arg503 36
Tryphanthrine -9.7 his428, leu392, leu492 3 ala396, ala395, arg503 27
Dicoumarin -9.3 ala395, leu392, Val494 2 his428, leu396 37
swertianin -9.3 his428, ala395, leu392, leu492 3 cys146, arg503, ala396 26
Diosmetin -9.3 his428, leu392, Val494 3 ala396, Val37, leu492 32
apigenin -9.3 leu492, leu392, his428, ala395 1 cys146 35
honokiol -9.3 ala396, ala395, his428, Val494,  
leu392, leu492
2 leu492, arg503 34
luteolin -9.3 Val494, leu392, leu492 3 his428, Val37, arg503 35
Thaliporphine -9.1 ala395, his428, leu392, leu492, Pro495 3 cys146, ala396, arg503 30
Oxymatrine -9 his428, Val494, leu392, ala396,  
ala395, Pro495
1 cys146, arg503 31
Wedelolactone -8.9 leu492, leu392, his428 2 ala396, cys146 22
Desmethylwedelolactone -8.9 his428, leu392, leu492 3 ala396, cys146 27
Berberine -8.9 ala396, his428, leu392, Val494, leu492 1 Thr399 30
andrographolide -8.9 ala395, his428, leu392, Val494, leu492 2 cys146, ala396 29
ladanein -8.9 ala396, leu392, Val494, leu492 2 his428, cys146 33
curcumin -8.8 leu492, ala396, leu392, leu492, Pro495 2 his428, cys146 41
genistein -8.8 leu492, ala396, ala395, leu392, Val494 2 his428, arg503 29
loganin -8.7 his428, leu392 2 ala396 25
epicatechin -8.6 his428, leu392, ala396 2 cys146, arg503 34
hypophyllanthin -8.6 leu492, leu392 2 arg503 32
Quercetin -8.5 Val494, leu492 1 ala396 29
silymarin/silibinin -8.5 Pro495, ala396, arg503, ala395 4 his428, arg503 40
Phyllanthin -8.4 his428, arg503, leu392, Pro495, Val494,  
leu492, ala396, ala395
0 n/a 42
lucidone -8.3 his428, leu392, Val494, leu492 3 cys146, ala395, ala396 35
Jatrorrhizine -8.3 ala396, leu392, Val494, leu492 2 cys146, his428 21
caruilignan c -8.1 ala396, his428, leu392, Val494, leu492 1 cys146, arg503 34
Verbenalin -8.1 his428, Pro495, Val494, leu492 4 cys146, arg503, ala396 33
geranyl acetone -8.1 his428, leu392, leu492, Val494,  
ala396, ala395
0 n/a 36
nobiletin -7.8 ala396 2 leu492 29
Tetradecanoic acid -7.4 ala396, his428, leu392, Val494, leu492 1 arg503 24
sofosbuvir -6.2 ala395, ile424, ala396, Val494, leu492, 
his428
2 arg503, Thr399 26
Abbreviations: hcV, hepatitis c virus; ns5B, nonstructural protein 5B; n/a, not available.
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Figure 3 Molecular surface representations of ns5B binding pocket with top docked ligands.
Notes: conformation of top ligands (binding energy -9 kcal/mol) inside binding pocket shown by sticks in dim gray. The protein-binding pocket is exposed in molecular 
surface representation (light blue), with the 12 interacting residues within 4 Å from ligand displayed by green sticks. Docking view of naringenin (A), tryphanthrine (B), 
dicoumarin (C), swertianin (D), diosmetin (E), apigenin (F), honokiol (G), luteolin (H), and thaliporphine (I).
Abbreviation: ns5B, nonstructural protein 5B.
new approach to analyze ADMET properties is time- and 
cost-effective. It also provides a less risky route for bring-
ing new therapies to patients.51 Nowadays, ADME analysis 
is performed at the early stages of drug discovery and is a 
part of high-throughput drug screening.52 ADMET predic-
tions are based on molecular descriptor values according 
to Lipinski’s Ro5. Ligands having suitable pharmaco-
logical and drug-like properties are considered vital for 
drug discovery process.44 They include properties such as 
blood–brain barrier (BBB) penetration,53 human intestinal 
absorption (HIA),54 aqueous solubility,55 and CYP450 
inhibition.56 Analysis of PK and PD properties is a crucial 
step for rational drug designing.32 In the current study, in 
silico method was employed using 30 filtered ligands that 
were selected upon drug-likeness properties assessed using 
Lipinski’s Ro5. The rule states that most orally adminis-
tered drugs have a molecular weight of less than 500 Da, 
and their log P-value is less than five. Also, they possess 
five or less hydrogen bond donor sites and ten or less 
hydrogen bond acceptor sites, hence predicting their oral 
bioavailability.57 The in silico models of ADMET proper-
ties use the quantitative structure–activity relationship, in 
which physicochemical properties to describe molecules are 
used to search for a relationship with an ADMET property 
graphically represented in Figure 4. The analysis was per-
formed by submitting the molecular structures of ligands 
on the admetSAR server and OSIRIS property explorer, 
and by using ADME descriptors of Discovery Studio 4.0 
for predicting various ADME properties.
The ADME profile of high-scoring ligands (–9 kcal/mol) 
in docking is precisely showing in Table 3. It is seen that 
diosmetin and luteolin have side effects on absorption 
through BBB and only oxymatrine exhibits poor absorption 
through human intestine. The tight junctions present between 
endothelial cells of brain capillaries are highly resistant and 
prevent uptake and delivery of polar drugs by the brain.58 
Penetration of BBB is required to minimize central nervous 
system-related consequences. It depends on factors such as 
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lipophilicity, molecular size, desolvation potential, pK
a
-to-
charge ratio, and hydrogen bond.59,60 Similar results were 
obtained for HIA and Caco-2 permeability where most of 
the high-scoring ligands showed positive result, with the 
only exception of oxymatrine and luteolin showing nega-
tive results. Thaliporphine and oxymatrine were observed 
to show inhibitory side effect for renal organic cation trans-
porter. For P-gp substrate, only half of the ligands showed 
positive result, whereas all ten ligands were non-inhibitors 
for P-gp inhibitor.
CYP450 belongs to superfamily of hemoproteins and is 
a group of isozymes that are involved in the metabolism of 
carcinogens, fatty acids, bile acids, steroids, and importantly 
of drugs and other xenobiotics.61 Thus, CYP enzymes play a 
major role in drug metabolism. Therefore, various CYP450 
substrate (2C9, 2D6, and 3A4) and CYP450 inhibitor (1A2, 
2C9, 2C19, 2D6, and 3A4) models are calculated during 
ADME profiling. All ten ligands were non-substrate for all 
CYP450 substrates (2C9, 2D6, 3A4), whereas oxymatrine 
and thaliporphine were found to be substrate for CYP450 
3A4 enzyme. The analysis showed that naringenin, tryphan-
thrine, diosmentin, apigenin, honokiol, and luteolin revealed 
high CYP inhibitory promiscuity, as these ligands inhibited 
most of the CYP450 inhibitors (1A2, 2C9, 2C19, 2D6, and 
3A4).30 The inhibition of CYP450 isoforms affects the drug 
metabolism and causes the accumulation of toxic levels.62 
It can be summarized from the results that dicoumarin and 
swertianin have the best ADME profile with good BBB, 
Figure 4 The journey of an oral drug candidate depicting the quantitative structure–activity relationship of physicochemical properties with absorption, distribution, 
metabolism, excretion, and toxicity.
Notes:  aDr is an injury caused by taking the medications. aDrs may occur following a single dose or prolonged administration of a drug or result from the combination 
of two or more drugs.
Abbreviations: MW, molecular weight; Psa, polar surface area.
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HIA, and non-inhibitors of CYP450 isoforms, which help 
in drug metabolism and its clearance from the body.30 The 
predicted ADME profile of all 30 filtered compounds is 
tabulated in Table S2.
Prediction of toxicity profile
Along with PK, a lead compound must also not show a threat 
to toxicity risks upon consumption; that is, it must have good 
PD properties.63 In the present study, ten qualitative classifi-
cation models were used, which included ligand’s biodegrad-
ability, developmental toxicity potentials, AMES toxicity, 
mutagenicity, carcinogenicity, irritancy, tumorigenicity, fish 
toxicity, honey bee toxicity, Tetrahymena pyriformis toxicity, 
and reproductive effectiveness (Table 4). Toxicity profile 
revealed that most of the compounds were not mutagenic, 
carcinogenic, and tumorigenic, were negative for AMES 
toxicity, and had no significant toxicity properties that can 
produce harmful effects in humans. However, there were a 
few exceptions. Also, only a few ligands showed toxicity 
effect among all 30 filtered compounds (Table S3).
Conclusion
In this  past decade there has been a great interest in exploi-
tation of phytochemicals for pharmaceutical use.64 It is not 
surprising that such studies has been carried out for hepatitis 
C also. HCV is a highly variable virus, having a rapid repro-
duction rate.65 Inhibition of NS5B, an RdRp, is therefore the 
principal option for the treatment of the disease caused by 
this virus. Treatments providing inhibitory activity include 
nucleotide analog inhibitors such as sofosbuvir. It should, 
however, be noted that sofosbuvir is used in combination with 
ribavirin and is considered as an add-on therapy. Such mul-
tidrug regimen is not only high in cost but also increases the 
side effects.66 Ribavirin and interferon therapies already have 
well-known consequences, including fatigue, influenza-like 
symptoms, hematologic abnormalities, and neuropsychiatric 
symptoms.67 Therefore, there is a need to find cheaper and 
efficient drugs for HCV treatment.
The present in silico studies provide insight into the 
inhibition of NS5B viral protein by plant-derived compounds 
which are more or equally potent to sofosbuvir. Many of the 
compounds also fulfill the ADMET criteria and thus can be 
formulated into a commercial drug. In the current investiga-
tion, a total of 84 compounds were screened and analyzed for 
their inhibitory action against NS5B protein. Molecular dock-
ing studies suggested ten highly active compounds, namely, 
naringenin, tryphanthrine, dicoumarin, swertianin, diosmetin, 
apigenin, honokiol, luteolin, thaliporphine, and oxymatrine T
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as HCV inhibitory drugs. These compounds showed strong 
binding affinity (greater than -9 kcal/mol) when docked 
against NS5B active site. The binding energies are much 
higher than the binding energy of the FDA-approved drug, 
sofosbuvir (-6.2 kcal/mol). These inhibitors also presented 
good molecular interactions (hydrogen and VdW) with the 
active site of NS5B. After ADMET analysis, it has been 
observed that among high-scoring ligands, dicoumarin and 
swertianin are fit for human consumption. They have a favor-
able druggability and good ADMET properties. Nowadays, 
in silico, in vitro, and in vivo ADMET tools constitute an 
integrated part of modern medicinal chemistry and drug 
discovery in terms of the early assessment of drug-exposure 
profile and safety performance. The full awareness of the 
benefits and limitations of each tool assures the right ques-
tions to be answered using right tools at the right time.68 The 
active compounds identified in this study can be used as an 
alternative treatment for HCV, especially in countries with 
poor socioeconomic conditions.
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Supplementary materials
Table S1 Medicinal plants with antiviral properties used in the current study
Compound Medicinal plant Family class
naringenin Citrus Grandis Osbeck Flavonoids
Diosmetin Pistacia chinensis Flavonoids
apigenin Eclipta alba Flavonoids
luteolin Eclipta alba Flavonoids
ladanein Marrubium peregrinum Flavonoids
genistein Genista tinctoria Flavonoids
epicatechin Acacia catechu Flavonoids
Quercetin Allium cepa Flavonoids
silymarin/silibinin Andrographuis paniculata Flavonoids
nobiletin Aurantii nobilis Flavonoids
Thaliporphine Mahonia leschenaultia alkaloids
Oxymatrine Sophora flavescens alkaloids
Jatrorrhizine Mahonia leschenaultia alkaloids
Berberine Mahonia leschenaultia alkaloids
honokiol Magnolia grandiflora lignans
Phyllanthin Phyllanthus amarus lignans
hypophyllanthin Phyllanthus amarus lignans
caruilignan c Swietenia macrophylla lignans
loganin Cornus officinalis iridoids
Verbenalin Verbena officinalis iridoids
Dicoumarin Viola yedoensis coumarins
Wedelolactone Eclipta alba coumarins
Tryphanthrine Wrightia tinctoria Quinazolines
swertianin Swertia chirata Xanthenes
Desmethylwedelolactone Eclipta alba Polphenols
andrographolide Andrographuis paniculata Diterpenoids
curcumin Curcuma longa Phenols
lucidone Lindera erythrocarpa chalcones
geranyl acetone Acacia concinna Terpenoids
Tetradecanoic acid Acacia concinna Fatty acid
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